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Abstract
Objective The objective of this study is to quantify volume
changes in the gross target volume (GTV) during preopera-
tive radiotherapy for extremity soft tissue sarcomas (ESTS).
Methods Twenty-seven patients with ESTS, treated with
preoperative radiotherapy, were included in this study.
Weekly cone-beam CT scans acquired for setup correction
were used for GTV delineation in order to quantify volume
changes over the course of treatment. Age, anatomical lo-
cation, tumour type and tumour volume were evaluated as
predictive factors for volume changes. Finally, the optimal
time point for adaptive intervention was quantified.
Results A GTV increase to a maximum of 28 % occurred in
five patients. Thirteen patients showed no change and nine
patients (all diagnosed with myxoid liposarcoma (MLS))
showed a GTV decrease to a maximum of 57 % of the
GTV volume at start of treatment. In the multivariate anal-
ysis, only the relative volume change for tumour type was
significant (p=0.001). The optimal time point for adaptive
intervention in non-MLS patients was the first week and for
MLS patients the third week.
Conclusions Volume changes were quantified during pre-
operative RT of ESTS. Volume decrease was observed only
in MLS patients. Individualised treatment resulting in plan
adaptations could result in a clinically useful volume reduc-
tion for MLS patients.
Keywords Soft tissue sarcomas .Preoperative radiotherapy .
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Introduction
Surgery is the standard management for extremity soft tissue
sarcomas (ESTS). Administration of (neo)adjuvant radio-
therapy (RT) is dependent on the site, size, grade, histolog-
ical subtype and pathologically assessed resection margins.
RT improves local control and possibly overall survival
while allowing higher extremity preservation rates [1–3].
In postoperative RT, the first 50 Gy is applied to the whole
surgically treated area which may be at risk of contamina-
tion, including the scar and drain sites. Generally, these
volumes are much larger than the sarcoma volume itself.
A boost is subsequently applied to the original tumour
location. The recommended dose for the boost is 10 Gy
when ample surgical resection margins are negative and
16–20 Gy when resection margins are positive, narrow or
indistinct. In preoperative RT, a conventional dose of 50 Gy
is prescribed to the gross primary tumour (the gross target
volume (GTV)), with a margin to include the volume that is
at risk for containing microscopic extension (the clinical
target volume (CTV)). A margin to account for geometrical
uncertainties is added to the CTV to generate the planning
target volume (PTV). Although there is a higher risk for
wound complications [4], preoperative RT is often pre-
ferred. Smaller RT fields and a lower total dose for preop-
erative RT seem to be important prognostic factors for
endpoints, such as fibrosis, oedema, arthrosis and bone
fractures [5–8].
The introduction of image-guided radiotherapy, by means
of, e.g. in-room cone-beam CT scan (CBCT), facilitates
improved verification of the volumetric behaviour and po-
sition of the tumour during treatment. The position of the
tumour relative to anatomical structures can change during
the 5 weeks of treatment due to variations in patient position
and/or changes in tumour volume. These changes in volume
are difficult to assess when electronic portal imaging (EPI)
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is used but can be visualised on CBCT due to its 3D nature
and improved soft tissue contrast. To realise smaller RT
fields, optimal information about the location of the tumour
(with respect to the bony anatomy) and the volumetric
behaviour during RT is essential. Visa versa, from a local
control point of view, field sizes need to be enlarged in case
of GTV increase.
Therefore, the purpose of this study is to quantify
changes in the GTV during preoperative RT of ESTS.
Methods
Patients and tumour characteristics
A group of 44 patients was retrospectively analysed. All
patients were scheduled for preoperative RT for ESTS.
Forty-two had various types of intermediate to high-grade
deep-seated primary ESTS, while two patients were diag-
nosed with aggressive fibromatosis.
Twenty-seven patients were treated on a linear accelera-
tor equipped with CBCT (Elekta Synergy, Elekta Oncology
Systems Ltd., Crawley, West Sussex, UK), augmented with
in-house developed software) [9]. All 27 patients were in-
cluded in the study, and their setup correction was based on
a CBCT-guided protocol. The remaining 17 patients were
treated on a linear accelerator without CBCT. Setup verifi-
cation for this patient group was performed with EPI. As
soft tissue registration is not possible with EPI, these
patients were not included in this study. The tumours were
categorised using the WHO classification for STS [10].
Classification was performed preoperatively by a Tru-cut
core biopsy or a small volume incision biopsy. The histo-
pathological grading of STS by Coindre [11] was used.
Preparation procedure
A planning CT scan was acquired in treatment position for
each patient. The treatment position (prone/supine, exo/endor-
otation of the lower limbs) depended on the location of the
tumour. The position was chosen individually to be confident
that an optimal treatment could be planned. Care was taken to
assure the patient’s comfort and to the position of the opposite
unaffected limb. Patients with a tumour in the buttock were
scanned in prone position using an ankle support. No addi-
tional immobilisation device was used. Several individual
immobilisation techniques were used for patients with
tumours in the upper and lower leg. Most of these patients
were scanned in supine position. The affected leg was fixated
with an individual thermoplastic cast around the knee and/or
the ankle. If necessary, the unaffected leg was lifted using
Styrofoam blocks. In some patients both legs were immobi-
lised. Skin marks were created on the patient for repositioning
in the treatment room. A planning CTscan and diagnostic MR
scan (T1 weighted, gadolinium enhanced) were acquired for
each patient in treatment position. Both scans were acquired
on the same day. The CTand MR scans were registered to the
bony anatomy using in-house developed software and diag-
nostic information from both scans was used to aid GTV
delineation.
Treatment
RT was administered by a linear accelerator with photon
energies of 6–10 MV, to a dose of 50 Gy in 25 fractions.
Planning and dose prescription were in conformity with the
ICRU 50/62 guidelines [12]. The aim of the treatment
planning was to spare the circumference of the long bones
as much as possible (e.g. to prevent fractures [7]). For
prevention of lymph oedema, at least one side of the skin
of the extremity had to be spared. The chosen techniques
changed during the overall time of this study from predom-
inantly 3D conformal fields towards full IMRT. CBCT scans
were acquired for setup verification based on bony anatomy,
according to an offline shrinking action level decision pro-
tocol [13]. For each patient, at least seven CBCT scans were
acquired; a minimum of two CBCT scans in the first week
followed by at least one CBCT scan each week.
GTV changes
To quantify changes in volume and position for each patient
during treatment, the GTV was delineated on the registered
MRI/planning CT scan, the GTV in the CBCT scans ac-
quired during the first two fractions and on the CBCT scans
during each week of treatment. Delineation was performed
with in-house developed software. With this software it was
possible to visualise all scans in one overview. Delineation
was performed after a registration on bony anatomy. To
reduce intra-observer variation, the original GTV was cop-
ied to the first CBCT scan and adjusted. Next, the GTV of
the first CBCT scan was copied to the second CBCT scan
and so on. The delineations were performed in the axial
view of the scans and verified in coronal and sagittal views.
An example of the GTV delineations is presented in Fig. 1.
The absolute and relative volumes of the GTV were calcu-
lated for all scans. An increase or decrease in volume was
defined by a change of 5 % in the relative volume. To acquire
the most reliable volume estimation at start of treatment, the
average GTV of the first two CBCT scans was used as a
reference volume (CBCT reference). The relative volume
changes were calculated in relation to CBCT reference to
quantify changes during the whole course of treatment.
Out of the calculated volumes, an estimation was made of
the GTV diameters. For that purpose, all GTVs were as-
sumed to be spherical.
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Adaptive radiotherapy
Bony anatomy registration simulates an online correction
strategy. Volume changes however cannot be corrected us-
ing a simple couch shift. Adaptive re-planning could be
considered as an alternative. To determine the optimal mo-
ment for such an adaptive intervention, the relative volume
changes were not only calculated in relation to the planning
CT scan but also in relation to the CBCT scan acquired
during each week of treatment. Subsequently, the overall
volume deviations (calculated as the root mean square
(RMS) volume difference between the first N CBCT scans
relative to the planning CT scan and the subsequent scans
relative to the Nth CBCT scan) were calculated. The N that
minimises the volume deviations indicates the optimal time
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with Vi the volume at scan i, Vp the volume of the planning
CT, and T the total number of scans.
In this paper, we only evaluate a single adaptive inter-
vention. We consider more than one adaptive intervention
currently not practical in daily patient management, taking
the time for re-scanning, re-delineation and re-planning into
account.
Statistical analysis
For statistical analysis SPSS version 17.0 (SPSS, Chicago,
Illinois) was used. Radiosensitivity of myxoid liposarcomas
(MLS) is known from literature [14–18]. Therefore, the
tumours were divided in two groups: non-MLS and MLS.
Differences in volume changes were analysed using the
Mann–Whitney U test. Furthermore, linear regression was
used to quantify the influence of age, anatomical location,
tumour type, and tumour volume. As there was a wide range
in tumour volumes, these were divided into three groups:
volume, <300 cm3, between 300 and 1,000 cm3 and
>1,000 cm3. These cut-off levels divided our population
into three equally sized subgroups of nine patients. A 5 %
significance level was used in all analyses.
Results
Patient and tumour characteristics
Patient and tumour characteristics are presented in Table 1.
The median age of the patients was 58 years (range, 19–79).
There were 15 male and 12 female patients. All tumours
were located in the lower extremities, 14 in the upper leg, 7
in the lower leg and 6 in the buttock. All tumours were
located deep. MLS and malignant fibrous histiocytoma
(MFH) were the most common subtypes, followed by
Fig. 1 Delineations of the GTVof a STS in the buttock, in axial slices.
In the upper row, the planning CT and the CBCT scans of the first two
fractions of weeks 1 and 2. In the lower row, the CBCT scans acquired
in weeks 3 to 6. The delineation of the planning CT scan (black) is
projected on each CBCT
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myxo-fibrosarcoma (MFS), synovial sarcoma (SS) and ma-
lignant peripheral nerve sheath tumours (MPNST). The
majority of patients received a dose of 50 Gy in 25 fractions,
followed 4–6 weeks later by surgery. Two patients received
a slightly different dose; one patient received 40 Gy, fol-
lowed by a boost of 10 Gy, another patient appeared to be
inoperable and was treated with a dose of 56 Gy, guided
according to anticipated normal tissue complications due to
its specific location. The time interval between the planning
CT-scan and the first treatment fraction was 7–20 days. The
mean GTV on the planning CT scan was 820 cm3 (range,
42–3,128 cm3). The mean GTV on CBCT reference was
829 cm3 (range, 34–3,513 cm3)
GTV volume and volume changes
The absolute and relative volumes, volume changes on
CBCT reference and last CBCT scan and the histological
subtypes of the sarcomas are presented in Table 2. The mean
absolute GTV volume change was −22 cm (range, −313 to
+292 cm3). The relative change was −5 % (range, −57 to
+28 %). The table is divided into three parts: top, patients
with GTV increase; middle, patients without significant
change in GTV; and bottom, patients with GTV decrease.
The volume changes during treatment are presented in
Fig. 2a–c. The x-axis shows the overall treatment time; the
start of the treatment is defined as day zero. The time of the
planning CT scan is indicated in negative numbers. The y-
axis shows the percentage of volume change during the
whole treatment. Not all CBCT scans were acquired during
the same fraction for each patient due to the applied setup
correction protocol. This accounts for the difference in
length of the lines indicating the volumes. The colours used
in the figures in this section are an indication for the histo-
logical type of ESTS (Fig. 2d). The yellow lines represent
MLS; purple=MFH; green=MFS; light green=SS; blue=
MPNST, and pink=others.
GTV increase was seen in five patients (Fig. 2a). One patient
(No. 18—Table 2) showed an initial GTV decrease of 10 %
before the start of treatment, followed by an increase of 28 %
towards the end of treatment. In general, the other patients in this
group, showed a constant GTV increase. Two patients had a
MPNST, two a MFH and one patient was classified in the
“other” group. Thirteen patients showed a rather constant
GTV during the whole course of treatment (Fig. 2b). Also in
this patient group, no clear relation was observed for a specific
histological subtype. Three patients showed an initial GTV
increase during the interval between planning CT scan and the
start of treatment. In one patient a GTV increase of 10 % was
observed up to the fourth week, but the volume remained
constant to the end of treatment in relation to the CBCT refer-
ence. Another patient, with a relatively small MFH, showed a
GTV decrease during the first 2 weeks, but showed no volume
decrease at the end of treatment compared with the CBCT
reference. Nine patients showed a GTV decrease (Fig. 2c). Only
one of these patients had a small GTV increase during the first
2 weeks. All patients in this group were classified as MLS. The
rate of decrease was similar but the time to onset differed. The
estimated diameters changes of the GTV were between −1.6
and +0.8 cm (mean, −0.2 cm).
The baseline volume distribution of the 16 non-MLS
patients (mean, 891 cm3; range, 48–3,246 cm3) was not
significantly different from the volume of the 11 MLS
patients (mean, 790 cm3; range, 81–1,839 cm3; p=0.69).
However, the relative volume change for non-MLS (mean,
+4 %; range, −4 to +28 %) vs. MLS patients (mean, −19 %;
range, −57 to +3 %) was significant (p=0.001). The relative
volume change was evaluated in the regression analysis.
Univariate regression analysis showed significance for age
(p=0.03) and tumour type (p<0.0001). No significance was
shown for anatomical location (p=0.76) or tumour volume
per group (<300 cm3, between 300 and 1,000 and
>1,000 cm3; p=0.48). In the multivariate regression analy-
sis, tumour type remained significant (p=0.001) but age was
no longer significant (p=0.48). As MLS patients were gen-
erally younger than non-MLS patients (43 vs. 60), age and
MLS are well correlated.
Adaptive radiotherapy
The optimal time point for adaptive intervention varied
between the first week and the fourth week. For two
Table 1 Clinicopathologic characteristics of patients and tumours
included in this study
Clinicopathologic characteristics
Factor n (range)










Malignant fibrous histiocytoma 6
Myxo-fibrosarcoma 2
Synovial sarcoma 2
Malignant peripheral nerve sheath tumours 2
Others 4
Volume (mean) 820 (42–3,128)cm3
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patients, there was no benefit in ART. On average, for the
non-MLS patients, the optimal time point was after week 1
(Fig. 3a) and for MLS patients after week 3 (Fig. 3b).
Discussion
Patients and tumour characteristics
The distribution between the subtypes in our patient group
differs from the general distribution, where MFH is found to
be the most common subtype [11]. This distribution how-
ever is a general distribution without difference in treatment
(pre/postoperative RT, chemotherapy and surgery) and loca-
tion. The patients selected for this study are only patients
with Extremity STS, all treated preoperatively. Furthermore,
when diagnosis is uncertain, pathologists tend to define the
specimen as MFH. In a multidisciplinary institute, experi-
enced in treatment of STS the diagnosis will in most cases
be more specific.
GTV changes
Criteria for staging and grading of STS have changed over
time, and therefore it is difficult to compare results of older
studies to results of present studies.
Miki et al. studied size and change of STS during preop-
erative RT in relation to treatment outcome [19]. In this
study, an increase of more than 10 % in tumour diameter
was noted in 31 % of the patients. No change or decrease
Table 2 Gross target volumes in CBCT reference and last CBCT scan and relative volume changes in relation to the CBCT reference
Patient No. Type CBCT reference (cm3) Last CBCT (cm3) Absolute change (cm3) Relative change (%)
18 MPNST 295 379 84 28
1 MFH 1,627 1,919 292 18
7 other 181 198 16 9
21 MPNST 3,246 3,513 267 8
27 MFH 508 546 39 8
11 MFS 1,175 1,212 37 3
5 MLS 542 558 16 3
22 MFH 48 49 1 3
12 MFS 2,414 2,456 42 2
8 MLS 1,779 1,807 28 2
4 SS 131 133 2 1
3 SS 77 78 1 1
10 Other 214 215 1 1
16 MFH 170 170 0 0
26 Other 1,406 1,388 −18 −1
13 MFH 1,580 1,537 −43 −3
25 MFH 217 208 −9 −4
2 Other 971 927 −44 −4
20 MLS 452 421 −31 −7
15 MLS 599 553 −46 −8
17 MLS 775 663 −112 −14
19 MLS 1,839 1,526 −313 −17
9 MLS 142 118 −24 −17
14 MLS 1,161 902 −260 −22
24 MLS 590 395 −195 −33
23 MLS 726 455 −271 −37
6 MLS 81 35 −46 −57
min 48 35 −313 −57
mean 850 828 −22 −5
max 3,246 3,513 292 28
The table is divided in three groups. On top, the patients with a GTV increase; in the middle, the patients without significant change in GTV; and at
the bottom, the patients with a GTV decrease
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was seen in the other patients. In our study, an increase or
decrease in tumour volume was defined by a change in the
relative volume of 5 %.
STSs in general are not responsive to radiation. Never-
theless, a similar radiation response for MLS as described in
literature [14–18] was also found in this study. However, not
all MLS patients showed a GTV decrease with respect to the
start of treatment. For two patients, no change was seen.
On the other hand, for a number of patients, a GTV
increase was seen during treatment time. One should be
aware of the fact that a GTV increase could lead to an under
dosage of the tumour and possibly to a failure of the preop-
erative RT treatment. In all patients, after visual assessment,
the GTV remained within the PTV; therefore, no patients
required re-planning due to GTV increase.
Magierowski et al. [20] presented similar results at the
14th Connective Tissue Oncology Society (CTOS) meeting.
They also performed a retrospective study of volume
changes in two pathological subtypes of STS: MLS (n=
10) and MFH (n=10). The GTV and bone were delineated
on a pre- and post-RT CT scan. They calculated the discrep-
ancies between the delineated contours of the GTV in both
scans using a deformable registration algorithm. In the MLS
patients, a median tumour reduction of 51 % was seen and in
the MFH patients a median growth of 11 %. However, they
found no statistical significance.
Delineation
Inter-observer variability could not be qualified as the delin-
eations of the GTV were performed once by only one
observer. Moreover, the delineations were performed on
CBCT scans, which have a lower image quality than the
planning CT scan or an MR scan. Volume changes between
planning CT scan and the reference CBCT scan and changes
during RT could also be the result of delineation uncertain-
ties. Delineation on MR scan could be more accurate, but
even in this modality significant inter- and intra-observer
variation have been demonstrated [21]. Furthermore, we
assumed that changes in the CTV behaved similar to
changes in the GTV. After generation of the CTV from the
GTV it was necessary in all patients to manually edit the
CTV near structures such as the fascia or bone, unless the
tumour was invasive at these areas. The image quality of the
CBCT scan was insufficient to distinguish structures such as
the fascia or small blood vessels, making delineation of the
CTV quite complicated. For a more accurate quantification
of target volumes, it may be advisable to repeat the study
with delineations of the GTV and edited CTV on repeat
scans of better image quality (CT or MRI). However, this
option is less practical. Further improvement of the image
quality of the CBCT scans may enable improved and more





Fig. 2 Relative GTV volumes of patients with GTV increase (a), GTV
without significant volume change (b) and GTV decrease (c) during
the overall treatment time. The colours (d) indicate the histological
type of ESTS. Yellow=MLS; purple=MFH; green=MFS; light green=
SS; blue=MPNST; pink=others
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Adaptive radiotherapy
The optimal CBCT scan as a reference scan for re-planning
appeared to be in week 1 for the non-MLS patients. For the
MLS patients, a re-planning in week 3 would be more useful.
For the latter, a reduction in field size and a possible reduction
in toxicity could be achieved. However, the clinical relevance
of ART must be considered if the tumour volume is already
small, or the volume change is in the direction of air. Further-
more, without accurate GTV delineation, reduction in field
size must be performed with great care. Even in postoperative
RT, the CTV covers the original invaded tissue.
Note that the optimal time points for ART were derived
from a geometrical surrogate: the RMS volume deviations
from the (adaptive) planning anatomy. Dosimetric evalua-
tion of actual adaptive re-planning should be performed to
validate these time points.
There is a possibility that the sarcoma continues to grow
in the interval between planning CT scan and start of treat-
ment (median, 11 days; range, 7–20 days). To rule out the
volume changes prior to RT, all changes have been per-
formed with respect to the start of treatment. Ideally patients
should start in the week of the planning CT scan. In that
case, volume changes could be calculated between the plan-
ning CT scan and consecutive CBCT-scans. The necessity to
re-plan in week 1 for the non-MLS group would also be
reduced if preparation time is shortened.
Statistics
The number of patients (27) in this study was too small to
differentiate between tumour behaviour in STS subtypes
other than MLS. In this study, all other subtypes were
evaluated as one group.
Conclusions
This study confirms that MLS regress more than other STS
and demonstrates the potential for more individual RT
treatment approach. Since positioning of ESTS patients
can sometimes be troublesome, direct visualisation of the
tumour by CBCT offers a significant advantage for target
alignment before treatment and allows monitoring of
therapy-induced changes during treatment. In patients with
a GTV decrease, the PTV encompasses excess normal tis-
sues with increasing normal tissue complication probability.
In patients with a GTV increase, there is a risk of a geo-
graphical miss. These phenomena are only truly appreciated
using 3D image-guided RT.
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